Views & Analysis International benchmarking and NICE Is NICE willing to change, or is it inflexible? It is being pressed to compare itself to other HTA organisations.
Views & Analysis Value for money of Health Technology Assessment Health Technology Assessment (HTA), despite the many definitions in use, has become almost synonymous with value for money (VfM). But just what is the value for money of HTA itself?
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
